197 related articles for article (PubMed ID: 37742004)
1. Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial.
Attaran F; Emami S; Sohrabi M; Malek M; Ajdarkosh H; Khoonsari M; Ismail-Beigi F; Khamseh ME
BMC Gastroenterol; 2023 Sep; 23(1):327. PubMed ID: 37742004
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Chehrehgosha H; Sohrabi MR; Ismail-Beigi F; Malek M; Reza Babaei M; Zamani F; Ajdarkosh H; Khoonsari M; Fallah AE; Khamseh ME
Diabetes Ther; 2021 Mar; 12(3):843-861. PubMed ID: 33586120
[TBL] [Abstract][Full Text] [Related]
3. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
Taheri H; Malek M; Ismail-Beigi F; Zamani F; Sohrabi M; Reza Babaei M; Khamseh ME
Adv Ther; 2020 Nov; 37(11):4697-4708. PubMed ID: 32975679
[TBL] [Abstract][Full Text] [Related]
4. Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Hooshmand Gharabagh L; Shargh A; Mohammad Hosseini Azar MR; Esmaeili A
Clin Res Hepatol Gastroenterol; 2024 Mar; 48(3):102279. PubMed ID: 38159676
[TBL] [Abstract][Full Text] [Related]
5. Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.
Lin YH; Zhang ZJ; Zhong JQ; Wang ZY; Peng YT; Lin YM; Zhang HP; Tian JQ
PLoS One; 2024; 19(5):e0302155. PubMed ID: 38701096
[TBL] [Abstract][Full Text] [Related]
6. Liver stiffness measurement identifies subclinical myocardial dysfunction in non-advanced non-alcoholic fatty liver disease patients without overt heart disease.
Sonaglioni A; Cerini F; Cerrone A; Argiento L; Nicolosi GL; Rigamonti E; Lombardo M; Rumi MG; Viganò M
Intern Emerg Med; 2022 Aug; 17(5):1425-1438. PubMed ID: 35302179
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT).
Lavynenko O; Abdul-Ghani M; Alatrach M; Puckett C; Adams J; Abdelgani S; Alkhouri N; Triplitt C; Clarke GD; Vasquez JA; Li J; Cersosimo E; Gastaldelli A; DeFronzo RA
Diabetes Obes Metab; 2022 May; 24(5):899-907. PubMed ID: 35014145
[TBL] [Abstract][Full Text] [Related]
8. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
[TBL] [Abstract][Full Text] [Related]
9. Left ventricular strain predicts subclinical atherosclerosis in nonadvanced nonalcoholic fatty liver disease patients.
Sonaglioni A; Cerini F; Nicolosi GL; Lombardo M; Rumi MG; Viganò M
Eur J Gastroenterol Hepatol; 2022 Jun; 34(6):707-716. PubMed ID: 35412487
[TBL] [Abstract][Full Text] [Related]
10. Response to pioglitazone in non-alcoholic fatty liver disease patients with
Wang Z; Du H; Zhao Y; Ren Y; Ma C; Chen H; Li M; Tian J; Xue C; Long G; Xu M; Jiang Y
Front Endocrinol (Lausanne); 2023; 14():1111430. PubMed ID: 37065735
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
[TBL] [Abstract][Full Text] [Related]
12. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.
Yoneda M; Honda Y; Ogawa Y; Kessoku T; Kobayashi T; Imajo K; Ozaki A; Nogami A; Taguri M; Yamanaka T; Kirikoshi H; Iwasaki T; Kurihashi T; Saito S; Nakajima A
BMJ Open Diabetes Res Care; 2021 Feb; 9(1):. PubMed ID: 33593749
[TBL] [Abstract][Full Text] [Related]
13. Significant Association between Subclinical Left Cardiac Dysfunction and Liver Stiffness in Metabolic Syndrome Patients with Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.
Apostu A; Malita D; Arnautu SF; Tomescu MC; Gaiță D; Popescu A; Mare R; Gidea R; Arnautu DA
Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837528
[No Abstract] [Full Text] [Related]
14. Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial.
Nesti L; Pugliese NR; Sciuto P; Trico D; Dardano A; Baldi S; Pinnola S; Fabiani I; Di Bello V; Natali A
Cardiovasc Diabetol; 2022 Sep; 21(1):181. PubMed ID: 36096863
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Cusi K; Orsak B; Bril F; Lomonaco R; Hecht J; Ortiz-Lopez C; Tio F; Hardies J; Darland C; Musi N; Webb A; Portillo-Sanchez P
Ann Intern Med; 2016 Sep; 165(5):305-15. PubMed ID: 27322798
[TBL] [Abstract][Full Text] [Related]
16. Visceral Adipose Tissue and Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes.
Nobarani S; Alaei-Shahmiri F; Aghili R; Malek M; Poustchi H; Lahouti M; Khamseh ME
Dig Dis Sci; 2022 Apr; 67(4):1389-1398. PubMed ID: 33788095
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
Kinoshita T; Shimoda M; Nakashima K; Fushimi Y; Hirata Y; Tanabe A; Tatsumi F; Hirukawa H; Sanada J; Kohara K; Irie S; Kimura T; Nakamura Y; Nishioka M; Obata A; Nakanishi S; Mune T; Kaku K; Kaneto H
J Diabetes Investig; 2020 Nov; 11(6):1612-1622. PubMed ID: 32329963
[TBL] [Abstract][Full Text] [Related]
18. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
Budd J; Cusi K
Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
[TBL] [Abstract][Full Text] [Related]
19. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
20. Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes.
Kahl S; Ofstad AP; Zinman B; Wanner C; Schüler E; Sattar N; Inzucchi SE; Roden M
Diabetes Obes Metab; 2022 Jun; 24(6):1061-1071. PubMed ID: 35166009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
